{"id":"W3165656578","doi":"10.1136/annrheumdis-2021-eular.1066","title":"POS0196 UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS: 56-WEEK DATA FROM THE PHASE 3 SELECT-PSA 2 STUDY","year":2021,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Probity Medical Research","funders":"Novartis Pharma; Sun Pharma; Genentech; Novartis Pharmaceuticals Corporation; Celgene; Gilead Sciences; Chugai Pharmaceutical; Amgen; Pfizer; Eli Lilly and Company","keywords":"Medicine; Psoriatic arthritis; Antirheumatic drugs; Refractory (planetary science); Antirheumatic Agents; Arthritis; Internal medicine; Pharmacology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001565014,0.0009919202,0.002133627,0.0002705589,0.000305771,0.0009952836,0.0003712819,0.0007894781,0.002583078],"category_scores_gemma":[0.001534362,0.0003900334,0.002273018,0.0004541789,0.0004122338,0.001036343,0.0002983536,0.002134038,0.0007541293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003829786,"about_ca_system_score_gemma":0.0004980493,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005807307,"about_ca_topic_score_gemma":0.001976291,"domain_scores_codex":[0.9995137,0.0002344733,0.00004427622,0.00007192549,0.00006022508,0.00007532811],"domain_scores_gemma":[0.9989342,0.0003697715,0.0003194928,0.00008878926,0.0000641284,0.0002235745],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8069874,0.004702813,0.02182879,0.002243615,0.006688526,0.0003358571,0.0001822809,0.00392526,0.01195764,0.0002727044,0.009247524,0.1316276],"study_design_scores_gemma":[0.6873084,0.133355,0.1492195,0.0004427852,0.008232081,0.001156397,0.0002762616,0.003893968,0.002917839,0.001035587,0.01199021,0.0001719888],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9772831,0.01441271,0.0004658849,0.0006218879,0.0002041669,0.0003853726,0.003725425,0.00009270164,0.002808755],"genre_scores_gemma":[0.9867408,0.00516758,0.0005657791,0.000990998,0.0001766996,0.0003695287,0.004694748,0.0000308837,0.001263058],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002583078,"threshold_uncertainty_score":0.008641303,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06919873261772448,"score_gpt":0.3493888414533753,"score_spread":0.2801901088356509,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}